Literature DB >> 35101289

Neurologic toxicity of carbamazepine in treatment of trigeminal neuralgia.

Rachel E Bridwell1, Samuel Brown2, Sean Clerkin3, Sara Birdsong2, Brit Long2.   

Abstract

Carbamazepine is a medication used to treat a variety of neurological and psychiatric conditions including seizure disorders, neuropathic pain syndromes, and bipolar disorder. Unfortunately, its pharmacokinetics and side effect profile may lead to significant toxicities due to its sodium channel blockade. In 2019, there were over 1500 cases of isolated carbamazepine toxicity reported to poison centers across the United States. Carbamazepine toxicity may result in vague neurological symptoms in milder cases, but in severe toxicity, it can cause cardiovascular instability, intractable seizures, and coma. In this article, we describe a case of a 40-year-old female who presented to a local emergency department with focal neurological deficits after repeated supratherapeutic dosing of carbamazepine.. This case highlights a key cerebrovascular accident mimic that emergency physicians should consider from acute toxicity that can be seen with carbamazepine in a patient who was taking the medication as prescribed. Published by Elsevier Inc.

Entities:  

Keywords:  Carbamazepine; Neurologic; Stroke-mimic; Supratherapeutic exposure; Toxicity

Mesh:

Substances:

Year:  2022        PMID: 35101289     DOI: 10.1016/j.ajem.2022.01.044

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  2 in total

1.  Carbamazepine Overdose after Psychiatric Conditions: A Case Study for Postmortem Analysis in Human Bone.

Authors:  Lucia Fernández-López; Rosanna Mancini; Maria-Concetta Rotolo; Javier Navarro-Zaragoza; Juan-Pedro Hernández Del Rincón; Maria Falcón
Journal:  Toxics       Date:  2022-06-13

2.  Characterization in Inhibitory Effectiveness of Carbamazepine in Voltage-Gated Na+ and Erg-Mediated K+ Currents in a Mouse Neural Crest-Derived (Neuro-2a) Cell Line.

Authors:  Po-Ming Wu; Hsin-Yen Cho; Chi-Wu Chiang; Tzu-Hsien Chuang; Sheng-Nan Wu; Yi-Fang Tu
Journal:  Int J Mol Sci       Date:  2022-07-17       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.